Lidocaine Spray Plus Oral Celecoxib for Pain Control During Hysterosalpingography

IUCD Complication Clinical Trial

Official title:
Lidocaine Spray Plus Oral Celecoxib for Pain Control During Hysterosalpingography: a Randomized Controlled Trial

Status Completed

Clinical Trial Summary

our aims to investigate the effectiveness of10% Lidocaine Spray plus oral celecoxib for Pain Control During Hysterosalpingography

Clinical Trial Description

hysterosalpingography can cause pain and discomfort in several ways: Use of the tenaculum to grasp the cervix and straighten the uterus for proper insertion; trans-cervical actions including measuring uterine depth, inserting the cannula; and injection of the dye ;

Study Design

Related Conditions & MeSH terms

IUCD Complication

Clinical Trial Details

NCT number	NCT04505657
Study type	Interventional
Source	Aswan University Hospital
Contact
Status	Completed
Phase	N/A
Start date	September 1, 2020
Completion date	September 27, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04517890` - Transdermal Lidocaine Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System	N/A
Not yet recruiting	`NCT04505943` - Vaginal Misoprostol and Dinoprostone and Isonicotinic Acid Hydrazide Prior to Copper Intrauterine Device Insertion	N/A
Not yet recruiting	`NCT04500002` - Isonicotinic Acid Hydrazide (INH) Pretreatment With Misoprostol Versus Misoprostol Alone in Missed Abortion	N/A
Completed	`NCT04499989` - Vaginal Isonicotinic Acid Hydrazide (INH) Administration Prior to T380A Intrauterine Device Insertion	Phase 4
Completed	`NCT04500015` - Vaginal Isonicotinic Acid Hydrazide Administration Prior to Intrauterine Device Insertion	Phase 4
Not yet recruiting	`NCT04505917` - Vaginal Misoprostol and Dinoprostone Prior to Copper Intrauterine Device Insertion in Women	N/A
Completed	`NCT04500028` - Vaginal Isonicotinic Acid Hydrazide Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System	Phase 4